- Guide to PHARMACOLOGY
Synonyms: AP-23573 | AP23573 | deforolimus | MK-8669
Compound class: Synthetic organic
Comment: Ridaforolimus is an investigational targeted and small-molecule inhibitor of the protein kinase mTOR . mTOR inhibition is hypothesised to provide maintenance therapy for patients with metastatic soft-tissue and bone sarcoma who generally have a poor prognosis despite receiving chemotherapy .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Ray-Coquard I, Le Cesne A. (2012)
A role for maintenance therapy in managing sarcoma.
Cancer Treat Rev, 38 (5): 368-78. [PMID:21843915]
2. Rivera VM, Squillace RM, Miller D, Berk L, Wardwell SD, Ning Y, Pollock R, Narasimhan NI, Iuliucci JD, Wang F et al.. (2011)
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens.
Mol Cancer Ther, 10 (6): 1059-71. [PMID:21482695]